ArticleEngineering (Beijing, China)2021
A Promising Anti-Cytokine-Storm Targeted Therapy for COVID-19: The Artificial-Liver Blood-Purification System.
Article in Engineering (Beijing, China), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04478539 (Clinical Efficacy and Safety of Extracorporeal Blood Purification to Control Hyperinflammation and Hypercoagulability in COVID-19 Patients), which is not on this map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical Efficacy and Safety of Extracorporeal Blood Purification to Control Hyperinflammation and Hypercoagulability in COVID-19 Patients
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 77 citations in OpenAlex.
- Immunomodulatory-based therapy as a potential promising treatment strategy against severe COVID-19 patients: A systematic review.International immunopharmacology · 2020Pooled it
- The blood purification therapy-based strategy effectively rescued the severe falciparum malaria patient experiencing cytokine storm-driven MODS.Frontiers in cellular and infection microbiology · 2025Article
- Blood filtering system for COVID-19 management: novel modality of the cytokine storm therapeutics.Frontiers in immunology · 2023Review
- Fighting cytokine storm and immunomodulatory deficiency: By using natural products therapy up to now.Frontiers in pharmacology · 2023Review
- Exhaustion and over-activation of immune cells in COVID-19: Challenges and therapeutic opportunities.Clinical immunology (Orlando, Fla.) · 2022Review
- Early Initiation of Extracorporeal Blood Purification Using the AN69ST (oXirisBrazilian journal of cardiovascular surgery · 2022Article
- Recent trends in Bi-based nanomaterials: challenges, fabrication, enhancement techniques, and environmental applications.Beilstein journal of nanotechnology · 2022Review
- VIVID:IEEE transactions on molecular, biological, and multi-scale communications · 2021Article
- Effect of artificial liver blood purification treatment on the survival of critical ill COVID-19 patients.Artificial organs · 2021Article
- Review
- Article
- Application of plasmapheresis for Covid-19 patients.Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy · 2021Article
- Kidney involvement in coronavirus-associated diseases (Review).Experimental and therapeutic medicine · 2021Review
- COVID-19 Pandemic: What about the Safety of Anti-Coronavirus Nanoparticles?Nanomaterials (Basel, Switzerland) · 2021Review
- Cytokine storm induced by SARS-CoV-2 infection: The spectrum of its neurological manifestations.Cytokine · 2021Review
- Immunological perspectives on the pathogenesis, diagnosis, prevention and treatment of COVID-19.Molecular biomedicine · 2021Review
- Detection and analysis of clinical features of patients with different types of coronavirus disease 2019.Journal of medical virology · 2021Article
- Matrix metalloproteinase 3 as a valuable marker for patients with COVID-19.Journal of medical virology · 2021Article
- Regen med therapeutic opportunities for fighting COVID-19.Stem cells translational medicine · 2021Article
- Treatment and prognosis of COVID-19: Current scenario and prospects (Review).Experimental and therapeutic medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.